POLR2A and breast cancer: The therapeutic landscape for BC continues to evolve, with emerging strategies combining immune checkpoint inhibitors and cytotoxic agents demonstrating synergistic effects.[48] Parallel developments in nanomedicine have yielded novel delivery platforms, including pH‐sensitive siRNA carriers targeting POLR2A,[49] advanced nanodelivery systems,[50] and photodynamic‐chemotherapy conjugates[51] that improve tumor localization while potentiating immune responses.